The US fiscal year 2023 omnibus spending package that President Biden signed into law 29 December promises to expedite reviews of drugs and biologics that sponsors plan to manufacture using advanced technologies.
US Funding Law Could Speed Approval Of Drugs And Biologics Manufactured In Advanced Ways
FY 2023 appropriations language requires HHS Secretary to designate advanced manufacturing technologies for expedited review, and to follow up with advice and meetings that could help move things along.
